Shore Capital Partners announced on January 24 that it completed a partnership with C2Dx, a medical device company based in Kalamazoo, Michigan. In addition to this partnership, Shore Capital Partners announced it, and C2Dx, was acquiring the Otolaryngology/Head and Neck Surgery (OHNS) family of products from Cook Medical.
The OHNS assets provide minimally invasive procedures for ear, nose and throat surgeons to help treat obstructive salivary disease, chronic ear disorders, nasal/sinus and skull base reconstruction and dysphagia.
Shore Capital Partners is a Chicago-based healthcare-focused lower middle-market private equity firm with offices in Nashville. It has approximately $3 billion of cumulative capital commitments through various investment vehicles.
C2Dx is a medical device company that invests in and refines the delivery of valuable, niche products to propel their growth and accessibility worldwide. Started in early 2019 and founded by industry experts, C2Dx is committed to providing medical products and customer service while continually evolving to ensure that healthcare providers have the devices and technology they need. It was founded by Plymouth Growth Partners.
The OHNS family of products is C2Dx’s fourth product line acquisition, joining its previous acquisitions of the Shaw Scalpel, STIC Intra-Compartmental Pressure Monitor and T/Pump Localized Temperature Therapy System. The financial terms were not disclosed.
According to data captured in the LevinPro HC database, this acquisition marks the eighth Medical Devices transaction of the year. In 2023, 111 Medical Devices transactions were announced.
